GlassScriptPhysician profile
Holly Lynn Colindres
NPI 1508175365
$6,886.96
in general payments reported to CMS, 2019-2025
37 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,220 · 2022: $940 · 2023: $1,552 · 2024: $1,558 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,551 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,551.28 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $876.46 | 2021-2025 | Ilumya |
| Janssen Biotech, INC. | $803.94 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $715.60 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $669.55 | 2021-2025 | Dupixent |
| Ucb, INC. | $372.60 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $359.20 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $301.68 | 2023-2025 | Sotyktu |
| Pfizer INC. | $300.79 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $297.68 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.23 | 2022-2025 | Spevigo |
| Incyte Corporation | $251.26 | 2021-2024 | Opzelura |
| Abbvie INC. | $191.89 | 2021-2025 | |
| Galderma Laboratories, L.P. | $181.25 | 2021-2025 | Nemluvio, Aklief |
| Mayne Pharma Commercial LLC | $164.23 | 2022-2025 | |
| Amgen INC. | $129.35 | 2021-2025 | Otezla, Otezla |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Colindres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.